Crestline Management LP reduced its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) by 30.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 329,043 shares of the biotechnology company’s stock after selling 142,650 shares during the period. Crestline Management LP owned about 0.22% of Rigel Pharmaceuticals worth $836,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. grew its holdings in Rigel Pharmaceuticals by 6.1% in the second quarter. Vanguard Group Inc. now owns 6,039,790 shares of the biotechnology company’s stock valued at $16,489,000 after purchasing an additional 348,755 shares during the period. State Street Corp grew its holdings in Rigel Pharmaceuticals by 4.3% in the second quarter. State Street Corp now owns 2,188,997 shares of the biotechnology company’s stock valued at $5,974,000 after purchasing an additional 90,640 shares during the period. Marshall Wace North America L.P. grew its holdings in Rigel Pharmaceuticals by 0.5% in the second quarter. Marshall Wace North America L.P. now owns 1,988,193 shares of the biotechnology company’s stock valued at $5,965,000 after purchasing an additional 9,867 shares during the period. Northern Trust Corp grew its holdings in Rigel Pharmaceuticals by 7.8% in the second quarter. Northern Trust Corp now owns 1,467,524 shares of the biotechnology company’s stock valued at $4,006,000 after purchasing an additional 106,148 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Rigel Pharmaceuticals by 0.8% in the second quarter. JPMorgan Chase & Co. now owns 1,461,550 shares of the biotechnology company’s stock valued at $3,990,000 after purchasing an additional 11,836 shares during the period. 74.51% of the stock is currently owned by institutional investors.

In other news, CFO Ryan D. Maynard sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $3.90, for a total value of $390,000.00. Following the transaction, the chief financial officer now owns 100,000 shares in the company, valued at $390,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.21% of the company’s stock.

Several equities analysts have recently weighed in on the company. Zacks Investment Research upgraded Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research report on Saturday, November 11th. ValuEngine downgraded Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Rigel Pharmaceuticals in a research report on Monday, November 6th. Jefferies Group restated a “buy” rating and issued a $5.00 target price on shares of Rigel Pharmaceuticals in a research report on Tuesday, September 5th. Finally, BMO Capital Markets restated a “buy” rating and issued a $5.00 target price on shares of Rigel Pharmaceuticals in a research report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Rigel Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $5.31.

Rigel Pharmaceuticals, Inc. (NASDAQ RIGL) opened at $3.61 on Wednesday. Rigel Pharmaceuticals, Inc. has a 1 year low of $1.94 and a 1 year high of $4.47.

Rigel Pharmaceuticals (NASDAQ:RIGL) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The business had revenue of $0.90 million for the quarter. Rigel Pharmaceuticals had a negative return on equity of 102.26% and a negative net margin of 354.14%. The business’s revenue was down 76.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.24) EPS. equities research analysts forecast that Rigel Pharmaceuticals, Inc. will post -0.56 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Rigel Pharmaceuticals, Inc. (RIGL) Shares Sold by Crestline Management LP” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/13/rigel-pharmaceuticals-inc-rigl-shares-sold-by-crestline-management-lp.html.

Rigel Pharmaceuticals Profile

Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Want to see what other hedge funds are holding RIGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL).

Institutional Ownership by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Receive News & Stock Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related stocks with our FREE daily email newsletter.